| elimination_half-life = 6–7 hours<ref name="LeeseTrang2015">{{cite journal|last1=Leese|first1=Philip T.|last2=Trang|first2=John M.|last3=Blum|first3=Robert A.|last4=de Groot|first4=Eleanor|title=An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin|journal=Clinical Pharmacology in Drug Development|volume=4|issue=2|year=2015|pages=112–120|issn=2160-763X|doi=10.1002/cpdd.175}}</ref>

 
'''Anamorelin''' ([[International Nonproprietary Name|INN]]) (developmental code names '''ONO-7643''', '''RC-1291''', '''ST-1291'''), also known as '''anamorelin hydrochloride''' ([[United States Adopted Name|USAN]], [[Japanese Accepted Name|JAN]]), is a [[non-peptide]], [[Oral administration|orally-active]], [[central nervous system|centrally-penetrant]], selective [[agonist]] of the [[growth hormone secretagogue receptor|ghrelin/growth hormone secretagogue receptor]] (GHSR) with [[orexigenic|appetite-enhancing]] and [[anabolic]] effects which is under development by [[Helsinn Healthcare SA]] for the treatment of [[cancer cachexia|cancer cachexia and anorexia]].<ref name="CurrowAbernethy2014">{{cite journal|last1=Currow|first1=David C|last2=Abernethy|first2=Amy P|title=Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome|journal=Future Oncology|volume=10|issue=5|year=2014|pages=789–802|issn=1479-6694|doi=10.2217/fon.14.14}}</ref><ref name="GarciaPolvino2009">{{cite journal|last1=Garcia|first1=José M.|last2=Polvino|first2=William J.|title=Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers|journal=Growth Hormone & IGF Research|volume=19|issue=3|year=2009|pages=267–273|issn=1096-6374|doi=10.1016/j.ghir.2008.12.003}}</ref><ref name="GarciaBoccia2015">{{cite journal|last1=Garcia|first1=José M|last2=Boccia|first2=Ralph V|last3=Graham|first3=Charles D|last4=Yan|first4=Ying|last5=Duus|first5=Elizabeth Manning|last6=Allen|first6=Suzan|last7=Friend|first7=John|title=Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials|journal=The Lancet Oncology|volume=16|issue=1|year=2015|pages=108–116|issn=1470-2045|doi=10.1016/S1470-2045(14)71154-4}}</ref>
